MDT to Evaluate the Survival Benefit of Patients With Advanced Gastric / Colorectal Cancer
- Conditions
- Multi-disciplinary Treatment
- Registration Number
- NCT03400657
- Lead Sponsor
- Peking University
- Brief Summary
This is a prospective, multicenter, non-interventional, controlled clinical study. Evaluate MDT performance and benefit analysis in patients with advanced gastric or colorectal cancer after MDT discussion under real medical practice.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 484
Inclusion Criteria
- Histopathological diagnosis of recurrent / metastatic gastric or colorectal cancer.
- Participate in formal MDT discussions at the Research Center.
- MDT decision-making at least two subjects involved in treatment.
- Patient informed consent and signed written consent.
Exclusion Criteria
- Early or locally advanced gastric cancer or colorectal cancer.
- Accept informal MDT discussions.
- MDT decisions recommend only a single subject for treatment of patients.
- MDT decisions recommend only palliative patients.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method overall survival From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
- Secondary Outcome Measures
Name Time Method Differences in overall survival after performing MDT at center 1 years Differences in overall survival after performing MDT at center
Trial Locations
- Locations (1)
Beijing Cancer Hospital
🇨🇳Beijing, Beijing, China
Beijing Cancer Hospital🇨🇳Beijing, Beijing, China